04/08/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/8/2020. This web page, updated on April 8, 2020, provides answers to frequently asked questions about Coronavirus Disease 2019 Basics; How COVID-19 Spreads; How to Protect Yourself; COVID-19 and Children; School Dismissals and Children; Preparing Your Home and Family for COVID-19; In Case of an Outbreak in Your Community; Symptoms and Testing; Higher Risk; Healthcare Professionals and Health Departments; COVID-19 and Funerals; What CDC is Doing; and COVID-19 and Animals. (Text)
04/08/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 4/8/2020. In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices to facilitate testing outside of laboratory settings. At present, based on current evidence, the World Health Organization recommends the use of these new point-of-care immunodiagnostic tests only in research settings. They should not be used in any other setting, including for clinical decision-making, until evidence supporting use for specific indications is available. (Text)
04/08/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 4/8/2020. This two-page tool has been designed to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2, the virus that causes novel coronavirus disease 2019 (COVID-19). The tool is a shortened version of the 2012 laboratory assessment tool that is widely used to assess national laboratory systems and the capacity of laboratories. (PDF)
04/08/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/8/2020. To ensure continuity of operations of essential functions, this interim guidance advises that critical infrastructure workers may be permitted to continue work following potential exposure to COVID-19, provided they remain asymptomatic and additional precautions are implemented to protect them and the community. (Text)
04/08/2020 12:00 AM EDT
Source: American Medical Association (AMA). Published: 4/8/2020. This guide includes information for physicians and health care professionals who want to support communities severely impacted by COVID-19. It tells how and where to volunteer—and things to consider before registering. For state agencies and institutions, the guide includes information on third-party organizations that can identify and match volunteers accordingly, as well as resources for credentialing in an emergency. (Text)
04/07/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/7/2020. This web page was updated on April 7, 2020, to include adescription of risk to dental health care personnel when providing emergency care during the COVID-19 pandemic; recommendations for contacting patients prior to emergency dental care; recommendations for providing emergency dental care to non-COVID-19 patients, including engineering controls, work practices, and infection control considerations; potential exposure guidance; and contingency and crisis planning. (Text)
04/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Smart Detect™ SARS-CoV-2 rRT-PCR Kit, which received an Emergency Use Authorization from the Food and Drug Administration on April 7, 2020. The Smart Detect™ SARS-CoV-2 rRT-PCR Kit is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
04/07/2020 12:00 AM EDT
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 4/7/2020. A number of cities in the United States are preparing alternative care facilities (ACFs) to augment surge capacity in response to the COVID-19 pandemic. But in some instances, it seems the use case or strategy for these facilities is unclear. This report provides recommendations for how ACFs can best be used in the immediate response to COVID-19. (Text)
04/07/2020 12:00 AM EDT
Source: Commonwealth Fund. Published: 4/7/2020. This report assesses the U.S. health system’s capacity to respond to COVID-19 compared to 16 countries — 10 that take part in the Commonwealth Fund’s annual international survey (Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom) plus six others that have experienced large numbers of confirmed COVID-19 cases (China, Italy, Singapore, South Korea, Spain, and Taiwan). (Text)
04/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/6/2020. This 11-page guidance provides a policy to help expand the capability of remote ophthalmic assessment and monitoring devices to facilitate patient care while reducing patient and healthcare provider contact and exposure to COVID-19 during the COVID-19 pandemic. (PDF)
04/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/6/2020. This one-hour webinar was held for device manufacturers and industry to discuss and answer questions on the recently issued, immediately in effect guidances on enforcement policy for personal protective equipment (PPE) during COVID-19. The two guidances discussed were Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Revised); and Enforcement Policy for Gowns, Other Apparel, and Gloves During the Coronavirus Disease (COVID-19) Public Health Emergency. (Video or Multimedia)
04/05/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/5/2020. This 16-page guidance provides a policy to help expand the availability and remote capabilities of infusion pumps and their accessories for health care professionals during the COVID-19 pandemic. These products are used to treat patients who require continuous infusion therapy during the COVID-19 public health emergency. (PDF)
04/04/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/4/2020. This web page was updated on April 4, 2020, to include considerations related to visitors and essential support persons to pregnant women who have known or suspected COVID-19 infection; prioritized testing of pregnant women with suspected COVID-19 at admission or who develop symptoms of COVID-19 during admission; testing of infants with suspected COVID-19 and isolation from other healthy infants; and determination of whether to keep a mother with known or suspected COVID-19 and her infant together or separated after birth on a case-by-case basis, using shared decision-making between the mother and the clinical team. (Text)
04/04/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/4/2020. This eight-page guidance provides a policy to help expand the availability of clinical electronic thermometers to address the COVID-19 public health emergency. These devices include both contact and non-contact clinical electronic thermometers. (PDF)
04/01/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 4/2020. Since the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS), the 2009-2010 H1N1 influenza pandemic, and the 2014-2016 Ebola outbreak in West Africa, authoritative guidance has been produced on how to conduct ethical research during emergencies. To ensure ethical research during the COVID-19 outbreak, this four-page document summarizes the key universal ethical standards. (PDF)
04/01/2020 12:00 AM EDT
Source: American College of Medical Toxicology (ACMT). Published: 4/1/2020. This one-hour, 22-minute webinar, part of the Medical and Public Health Considerations of COVID-19 webinar series, was presented for participants to understand role of ACE2 (Angiotensin Converting Enzyme 2) and ARBs (angiotensin-receptor blockers) in SARS-CoV2 (nCoV19) viral entry, understand the impact of NSAIDS (nonsteroidal anti-inflammatory drugs) on ACE, and discuss the roles NSAIDS may play in COVID19 severity. Speakers also discuss Remdesivir's pertinence to COVID-19, and updates from the pandemic's front lines. (Video or Multimedia)
03/26/2020 12:00 AM EDT
Source: American College of Medical Toxicology (ACMT). Published: 3/26/2020. This 54-minute webinar, part of the Medical and Public Health Considerations of COVID-19 webinar series, explores ways in which medical toxicologists who have a bedside service may be able to start to utilize conventional and non-conventional ways of providing medical toxicology consultations through telehealth during the COVID-19 pandemic. (Video or Multimedia)
03/25/2020 12:00 AM EDT
Source: American College of Medical Toxicology (ACMT). Published: 3/25/2020. This one-hour, three-minute webinar, part of the Medical and Public Health Considerations of COVID-19 webinar series, features leading medical toxicologists and experts in the care of poisoned patients who discuss the use of, and potential adverse effects with, chloroquine and hydroxychloroquine as physicians consider these therapies to treat patients with COVID-19; the current use of these drugs for COVID-19 in France; and the potential adverse effects when used for therapeutic purposes, in excessive doses, and in overdose. (Video or Multimedia)
03/24/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 3/24/2020. This five-page case report form for COVID-19 is intended to provide member states with a standardized approach to collect clinical data in order to better understand the natural history of disease. It has three modules to be used for the first day of admission to the health center, the first day of admission to ICU or high dependency unit, and upon discharge or death. (PDF)
03/21/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 3/21/2020. To help an organization prepare for the possible spread of COVID-19 and other illnesses, ensure that an emergency operations plan includes key COVID-19 prevention strategies and covers people at increased risk for serious illness, detailed in this guidance. This includes but is not limited to unsheltered homeless, older adults, and people with underlying conditions such as heart or lung disease or diabetes. (Text)
03/16/2020 12:00 AM EDT
Source: Hastings Center. Published: 3/16/2020. This report is designed for use within a health care institution’s preparedness work, supplementing public health and clinical practice guidance on COVID-19. It aims to help structure ongoing discussion of significant, foreseeable ethical concerns arising under contingency levels of care and potentially crisis standards of care. (Text)
03/01/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 3/2020. This 36-page document presents a Global Research Roadmap with immediate, mid-term, and longer-term priorities to build a robust global COVID-19 research response on the basis of the deliberations during the Global Research Forum on research and innovation for COVID-19 held on March 2, 2020. The global imperative for the research community is to maintain a high-level discussion platform which enables consensus on strategic directions, nurtures scientific collaborations, and supports optimal and rapid research to address crucial gaps, without duplication of efforts. (PDF)
.png)
No hay comentarios:
Publicar un comentario